Karyopharm Therapeutics Newsroom

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3

Futu NewsNov 15 20:33

Cautious Hold Rating on Karyopharm Therapeutics Amid Incremental Revenue Growth and Pending Clinical Trial Outcomes

TipRanksNov 8 15:31

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $5

Futu NewsNov 6 21:38

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

BenzingaNov 6 21:24

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3

Futu NewsNov 6 20:34

Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 6 16:33

H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7

Futu NewsNov 6 01:31

Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating

TipRanksNov 6 00:39

Karyopharm Therapeutics Analyst Ratings

BenzingaNov 1 17:51

Barclays Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 1 15:32

H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7

Futu NewsNov 1 00:31

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Cuts Target Price to $4

Futu NewsOct 23 20:31

Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)

TipRanksOct 23 19:42

Karyopharm Therapeutics: A Cautious Hold Amid Steady Performance and Pipeline Uncertainties

TipRanksAug 9 17:49

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

BenzingaAug 8 04:32

Karyopharm Therapeutics Price Target Cut to $5.00/Share From $8.00 by Baird

Dow JonesAug 8 00:00

Karyopharm Therapeutics Analyst Ratings

BenzingaAug 7 23:50

Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5

BenzingaAug 7 23:50

Karyopharm Therapeutics (KPTI) Gets a Buy From RBC Capital

TipRanksAug 7 19:27

Buy Rating Affirmed for Karyopharm Therapeutics Amid Strong Q2 Performance and Positive Xpovio Sales Outlook

TipRanksAug 7 18:46